NCT04362111View on ClinicalTrials.gov

Early Treatment of Cytokine Storm Syndrome in Covid-19

PHASE3CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

June 1, 2023

Conditions
Cytokine StormCOVID-19
Interventions
DRUG

Anakinra

The active treatment group will receive anakinra 100 mg subcutaneously every 6-12 hours for a period of 10 days

DRUG

Normal saline

The control group will receive normal saline placebo subcutaneously every 6-12 hours for period of 10 days

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT04362111 - Early Treatment of Cytokine Storm Syndrome in Covid-19 | Biotech Hunter | Biotech Hunter